Acción NAMS FRAZIER LIFESCIENCES ACQUISITION CORPORATION
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Frazier Lifesciences Acquisition Corporation

Acciones

NAMS

NL00150012L7

Precio de cierre Nasdaq
Otros sitios de cotización
 00:00:00 27/06/2024 		Varia. Cinco días. Varia. 1 de enero.
19,54 EUR -1,06 % Gráfico intradía de Frazier Lifesciences Acquisition Corporation +8,44 % +74,93 %
11/06 NewAmsterdam Pharma obtiene otra patente estadounidense que amplía la protección de la propiedad intelectual del obicetrapib hasta julio de 2043 MT
10/06 Transcript : NewAmsterdam Pharma Company N.V. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 10:40 AM

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
NewAmsterdam Pharma Gets Another US Patent Extending IP Protection for Obicetrapib Until July 2043
NewAmsterdam Pharma Announces Issuance of Composition of Matter Patent for Obicetrapib by the United States Patent and Trademark Office
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in June
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in June
NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings
NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings
NewAmsterdam Pharma Company N.V. to Present New Clinical and Preclinical Data Highlighting Obicetrapib's Impact on Key RiskFactors for Cardiovascular Disease at Upcoming Medical Meetings
Earnings Flash (NAMS) NEWAMSTERDAM PHARMA N.V. Reports Q1 Revenue $1.4M
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
NewAmsterdam Pharma Company N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024
NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024
NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease
NewAmsterdam Pharma Company N.V. Enrolls over 9,000 Patients in Pivotal Phase 3 Prevail Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease
NewAmsterdam Pharma Names Juliette Audet Chief Business Officer
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción NAMS
  4. Noticias Frazier Lifesciences Acquisition Corporation
  5. Otros idiomas